Metformin activates the STING/IRF3/IFN-β pathway by inhibiting AKT phosphorylation in pancreatic cancer

The anti-diabetes drug metformin has emerged as a promising antitumor agent in pancreatic ductal adenocarcinoma (PDAC) among other cancers by promoting the infiltration of immune cells in the tumor microenvironment (TME). However, the mechanisms underlying the antitumor effects of metformin in PDAC...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Am J Cancer Res
Prif Awduron: Ren, Dianyun, Qin, Gengdu, Zhao, Jingyuan, Sun, Yan, Zhang, Bin, Li, Dan, Wang, Bo, Jin, Xin, Wu, Heshui
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: e-Century Publishing Corporation 2020
Pynciau:
Original Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7539786/
https://ncbi.nlm.nih.gov/pubmed/33042621
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg